|
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy Subjects
RECRUITINGPhase 1Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd
Actively Recruiting
PhasePhase 1
SponsorGuangdong Hengrui Pharmaceutical Co., Ltd
Started2025-10-08
Est. completion2026-03
Eligibility
Age18 Years – 55 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07200596
Summary
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single-dose subcutaneous injection of SHR-3045 in healthy subjects.
Eligibility
Age: 18 Years – 55 YearsHealthy volunteers accepted
Inclusion Criteria: 1. Subjects with ability to understand the trial procedures and possible adverse events, voluntary participation in the trial. 2. Subjects who can provide written informed consent. 3. Males or females aged 18-55 years (both inclusive). 4. Males with body weight ≥ 50 kg, or females with body weight ≥ 45 kg, body mass index (BMI) 19-28 kg/m2 (both inclusive). 5. No clinically significant abnormalities in the medical history, general physical examinations, vital signs and laboratory tests. Exclusion Criteria: 1. Participation in clinical trials of other investigational drugs or medical devices within 3 months prior to screening. 2. Known or suspected history of drug abuse. 3. Addiction to tobacco and alcohol. 4. Individuals who are unable to adhere to the dietary requirements of this trial during the study period. 5. Judged by the investigator, there are any other conditions that interfere with the results evaluation of the trial.
Conditions2
ArthritisRheumatoid Arthritis (RA
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 1
SponsorGuangdong Hengrui Pharmaceutical Co., Ltd
Started2025-10-08
Est. completion2026-03
Eligibility
Age18 Years – 55 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07200596